Salidroside inhibits osteoclast differentiation based on osteoblast-osteoclast interaction via HIF-1α pathway

Abstract

This study investigated the regulatory potential of salidroside (SAL), a primary active compound in Rhodiola rosea L., on osteoclast differentiation by modulating the hypoxia-inducible factor 1-alpha (HIF-1α) pathway in osteoblasts. Luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were employed to validate whether the receptor activator of nuclear factor-κB ligand (RANKL) is the downstream target gene of HIF-1α in osteoblasts. The study also utilized lipopolysaccharide (LPS)-induced mouse osteolysis to examine the impact of SAL on osteolysis in vivo. Furthermore, conditioned medium (CM) from SAL-pretreated osteoblasts was used to investigate the paracrine effects on osteoclastogenesis through the HIF-1α pathway. Hypoxic condition-induced overexpression of HIF-1α upregulated RANKL levels by binding to the RANKL promoter and enhancing transcription in osteoblastic cells. In vivo, SAL significantly alleviated bone tissue hypoxia and decreased the expression of HIF-1α by downregulating the expression of RANKL, vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), and angiopoietin-like 4 (ANGPTL4). In the paracrine experiment, conditioned media from SAL-pretreated osteoblasts inhibited differentiation through the HIF-1α/RANKL, VEGF, IL-6, and ANGPTL4 pathways. RANKL emerges as the downstream target gene regulated by HIF-1α in osteoblasts. SAL significantly alleviates bone tissue hypoxia and bone loss in LPS-induced osteolysis through the HIF-1α/RANKL, VEGF, IL-6, and ANGPTL4 pathways. SAL inhibits osteoclast differentiation by regulating osteoblast paracrine secretion.

Keywords

Salidroside / Hypoxia-inducible factor-1α / Osteoblast / Osteoclast / Osteoclastogenesis

References

[1] Reid I R, Billington E O. Drug therapy for osteoporosis in older adults. Lancet. 2022; 399(10329):1080-1092. https://doi.org/10.1016/S0140-6736(21)02646-5.

[2] Jiajue R, Qi X, Jiang Y, et al. Incident fracture risk in type 2 diabetic postmenopausal women in mainland China: peking vertebral fracture study. Calcif Tissue Int. 2019; 105(5):466-475. https://doi.org/10.1007/s00223-019-00598-x.

[3] Fischer V, Haffner-Luntzer M. Interaction between bone and immune cells: implications for postmenopausal osteoporosis. Semin Cell Dev Biol. 2022; 123:14-21. https://doi.org/10.1016/j.semcdb.2021.05.014.

[4] Zeng Q, Li N, Wang Q, et al. The prevalence of osteoporosis in China, a nationwide, multicenter DXA Survey. J Bone Miner Res. 2019; 34(10):1789-1797. https://doi.org/10.1002/jbmr.3757.

[5] LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33(10):2049-2102. https://doi.org/10.1007/s00198-021-05900-y.

[6] Ensrud KE.Bisphosphonates for postmenopausal osteoporosis. JAMA. 2021; 325(1):96. https://doi.org/10.1001/jama.2020.2923.

[7] Tao Z, Wang J, Wen K, et al. Pyroptosis in osteoblasts: a novel hypothesis underlying the pathogenesis of osteoporosis. Front Endocrinol (Lausanne). 2020; 11:548812.

[8] Meng X, Wielockx B, Rauner M, et al. Hypoxia-inducible factors regulate osteoclasts in health and disease. Front Cell Dev Biol. 2021; 9:658893. https://doi.org/10.3389/fcell.2021.658893.

[9] Todd VM, Johnson RW. Hypoxia in bone metastasis and osteolysis. Cancer Lett. 2020; 489:144-154. https://doi.org/10.1016/j.canlet.2020.06.004.

[10] Stegen S, Carmeliet G. Hypoxia, hypoxia-inducible transcription factors and oxygen-sensing prolyl hydroxylases in bone development and homeostasis. Curr Opin Nephrol Hypertens. 2019; 28(4):328-335. https://doi.org/10.1097/MNH.0000000000000508.

[11] Tirpe AA, Gulei D, Ciortea SM, et al. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci. 2019; 20(24):6140. https://doi.org/10.3390/ijms20246140.

[12] Lin C, McGough R, Aswad B, et al. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res. 2004; 22(6):1175-1181. https://doi.org/10.1016/j.orthres.2004.03.002.

[13] Nguyen VT, Nardini M, Ruggiu A, et al. Platelet lysate induces in human osteoblasts resumption of cell proliferation and activation of pathways relevant for revascularization and regeneration of damaged bone. Int J Mol Sci. 2020; 21(14):5123. https://doi.org/10.3390/ijms21145123.

[14] Knowles HJ, Cleton-Jansen AM, Korsching E, et al. Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J. 2010; 24(12):4648-4659.

[15] Niu X, Chen Y, Qi L, et al. Hypoxia regulates angeogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor-1α pathway. Cytokine. 2019; 113:117-127. https://doi.org/10.1016/j.cyto.2018.06.022.

[16] Li W, Zhou X, Jiang T, et al. Positive effect of Gushukang on Type-H vessel and bone formation. Front Cell Dev Biol. 2020; 8:265. https://doi.org/10.3389/fcell.2020.00265.

[17] Yuan H, Xiao L, Min W, et al. Bu-Shen-Tong-Luo Decoction prevents bone loss via inhibition of bone resorption and enhancement of angiogenesis in ovariectomy-induced osteoporosis of rats. J Ethnopharmacol. 2018; 220:228-238. https://doi.org/10.1016/j.jep.2018.01.007.

[18] Wang YF, Chang YY, Zhang XM, et al. Salidroside protects against osteoporosis in ovariectomized rats by inhibiting oxidative stress and promoting osteogenesis via Nrf2 activation. Phytomedicine. 2022; 99:154020. https://doi.org/10.1016/j.phymed.2022.154020.

[19] Guo Q, Yang J, Chen Y, et al. Salidroside improves angiogenesis-osteogenesis coupling by regulating the HIF-1α/VEGF signalling pathway in the bone environment. Eur J Pharmacol. 2020; 884:173394. https://doi.org/10.1016/j.ejphar.2020.173394.

[20] Liu W, Wang Z, Yang J, et al. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice. Open Biol. 2019; 9(5):180262. https://doi.org/10.1098/rsob.180262.

[21] Xu M, Sun S, Ge J, et al. Bupleurum chinense polysaccharide improves LPS-induced senescence of RAW264.7 cells by regulating the NF-κB signaling pathway. Evid Based Complement Alternat Med. 2020; 2020:7060812.

[22] Sharma Y, Ahmad A, Yavvari PS, et al. Targeted SHP-1 silencing modulates the macrophage phenotype, leading to metabolic improvement in dietary obese mice. Mol Ther Nucleic Acids. 2019; 16:626-636. https://doi.org/10.1016/j.omtn.2019.04.020.

[23] Qiu Z, Li L, Huang Y, et al. Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway. J Orthop Translat. 2022; 33:55-69. https://doi.org/10.1016/j.jot.2022.01.003.

[24] Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015; 5(5):378-389. https://doi.org/10.1016/j.apsb.2015.05.007.

[25] Chen W, Wu P, Yu F, et al. HIF-1α regulates bone homeostasis and angiogenesis, participating in the occurrence of bone metabolic diseases. Cells. 2022; 11(22):3552. https://doi.org/10.3390/cells11223552.

[26] Ono T, Hayashi M, Sasaki F, et al. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020; 40:2. https://doi.org/10.1186/s41232-019-0111-3.

[27] McDonald MM, Khoo WH, Ng PY, et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell. 2021; 184(5):1330-1347. https://doi.org/10.1016/j.cell.2021.02.002.

[28] Meng X, Lin Z, Cao S, et al. Estrogen-mediated downregulation of HIF-1α signaling in B lymphocytes influences postmenopausal bone loss. Bone Res. 2022; 10(1):15. https://doi.org/10.1038/s41413-022-00189-x.

[29] Wu Y, Ma Y, Li J, et al. The bioinformatics and metabolomics research on anti-hypoxic molecular mechanisms of Salidroside via regulating the PTEN mediated PI3K/Akt/NF-κB signaling pathway. Chin J Nat Med. 2021; 19(6):442-453.

[30] Xiong Y, Wang Y, Xiong Y, et al. Protective effect of Salidroside on hypoxia-related liver oxidative stress and inflammation via Nrf2 and JAK2/STAT3 signaling pathways. Food Sci Nutr. 2021; 9(9):5060-5069. https://doi.org/10.1002/fsn3.2459.

[31] Costa-Rodrigues J, Fernandes A, Fernandes MH. Reciprocal osteoblastic and osteoclastic modulation in co-cultured MG63 osteosarcoma cells and human osteoclast precursors. J Cell Biochem. 2011; 112(12):3704-3713. https://doi.org/10.1002/jcb.23295.

[32] Crockett JC, Mellis DJ, Scott DI, et al. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int. 2011; 22(1):1-20. https://doi.org/10.1007/s00198-010-1272-8.

[33] Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007; 117(6):1616-1626. https://doi.org/10.1172/JCI31581.

[34] Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021; 39(1):19-26. https://doi.org/10.1007/s00774-020-01162-6.

[35] Han Y, You X, Xing W, et al. Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res. 2018; 6:16. https://doi.org/10.1038/s41413-018-0019-6.

[36] Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013; 123(2):666-681.

[37] Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012; 18(3):405-412. https://doi.org/10.1038/nm.2653.

[38] Wang H, Cao X, Guo J, et al. BNTA alleviates inflammatory osteolysis by the SOD mediated anti-oxidation and anti-inflammation effect on inhibiting osteoclastogenesis. Front Pharmacol. 2022; 13:939929. https://doi.org/10.3389/fphar.2022.939929.

[39] Song C, Yang X, Lei Y, et al. Evaluation of efficacy on RANKL induced osteoclast from RAW264.7 cells. J Cell Physiol. 2019; 234(7):11969-11975. https://doi.org/10.1002/jcp.27852.

[40] Wu X, Zhao K, Fang X, et al. Inhibition of lipopolysaccharide-induced inflammatory bone loss by Saikosaponin D is associated with regulation of the RANKL/RANK pathway. Drug Des Devel Ther. 2021; 15:4741-4757. https://doi.org/10.2147/DDDT.S334421.

[41] Sharma K, Kumar S, Prakash R, et al. Chebulinic acid alleviates LPS-induced inflammatory bone loss by targeting the crosstalk between reactive oxygen species/NFκB signaling in osteoblast cells. Free Radic Biol Med. 2023; 194:99-113. https://doi.org/10.1016/j.freeradbiomed.2022.11.026.

[42] Hu J, Li X, Chen Y, et al. The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF-κB and CD9/gp130/STAT3 signalling pathway. J Cell Mol Med. 2020; 24(2):1893-1905. https://doi.org/10.1111/jcmm.14885.

[43] Park HJ, Gholam ZM, Suh JH, et al. Dauricine protects from LPS-induced bone loss via the ROS/PP2A/NF-κB axis in osteoclasts. Antioxidants (Basel). 2020; 9(7):588. https://doi.org/10.3390/antiox9070588.

[44] Bordukalo-Nikšić T, Kufner V, Vukičević S. The role of BMPs in the regulation of osteoclasts resorption and bone remodeling: from experimental models to clinical applications. Front Immunol. 2022; 13:869422. https://doi.org/10.3389/fimmu.2022.869422.

[45] Veis D J, O'Brien C A. Osteoclasts, master sculptors of bone. Annu Rev Pathol. 2023; 18:257-281. https://doi.org/10.1146/annurev-pathmechdis-031521-040919.

[46] Da W, Tao L, Zhu Y. The role of osteoclast energy metabolism in the occurrence and development of osteoporosis. Front Endocrinol (Lausanne). 2021; 12:675385. https://doi.org/10.3389/fendo.2021.675385.

[47] Tao H, Li W, Zhang W, et al. Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways. Pharmacol Res. 2021; 174:105967. https://doi.org/10.1016/j.phrs.2021.105967.

[48] Andreev D, Liu M, Weidner D, et al. Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin. J Clin Invest. 2020; 130(9):4811-4830. https://doi.org/10.1172/JCI134214.

[49] Agidigbi T S, Kim C. Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases. Int J Mol Sci. 2019; 20(14):3576. https://doi.org/10.3390/ijms20143576.